Molecular Cancer Therapeutics 2022 May 2 [Link] Raffit Hassan, Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho Abstract Mesothelin targeting CAR T cells have limited activity in patients. In this study, we sought to determine if efficacy of anti-mesothelin CAR T…

Read More

The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…

Read More

ESMO Open 2022 April 12 [Link] M Mark, S Rusakiewicz, M Früh, S Hayoz, F Grosso, M Pless, P Zucali, G L Ceresoli, A Maconi, M Schneider, P Froesch, D Tarussio, F Benedetti, J Dagher, L Kandalaft, R von Moos, S Tissot-Renaud, S Schmid, Y Metaxas Abstract Background: The SAKK 17/16 study showed promising efficacy…

Read More

Lung Cancer 2022 March 21 [Link] Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Xiaowu Sun, Rachael Lawrance, Xiaoqing Zhang, Melinda J Daumont, Bryan Bennett, Mike McKenna, Paul Baas Abstract Objective: In CheckMate 743 (NCT02899299), nivolumab…

Read More

European Journal of Cancer 2022 March 28 [Link] Giuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, Alessio Cortellini, Marta Ponzano, Emilio Francesco Giunta, Sara Elena Rebuzzi, Samuel Chan, Vittorio Gebbia, Ronwyn van Eeden, Alfredo Addeo, Christian Ottensmeier Abstract Background: Randomised controlled trials (RCTs) with systemic therapies for patients with pre-treated mesothelioma have reported equivocal efficacy results…

Read More

Lung Cancer 2022 March 2 [Link] Alexander Davis, Helen Ke, Steven Kao, Nick Pavlakis Abstract The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence…

Read More

JAMA Network Open 2022 March 1 [Link] Tomer Meirson, Francesca Pentimalli, Francesco Cerza, Giovanni Baglio, Steven G Gray, Pierpaolo Correale, Marija Krstic-Demonacos, Gal Markel, Antonio Giordano, David Bomze, Luciano Mutti Abstract Importance: Some recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their impact on quality of life and overall survival…

Read More

Molecular and Clinical Oncology 2022 April [Link] Erika Rijavec, Federica Biello, Giulia Barletta, Chiara Dellepiane, Carlo Genova Malignant pleural mesothelioma (MPM) is considered a relatively uncommon disease but its incidence is increasing worldwide. Patients affected by MPM have a very severe prognosis and have been often occupationally and environmentally exposed to asbestos. In recent years,…

Read More

European Journal of Oncology Nursing 2022 February 15 [Link] Anna C Bibby, Anna J Morley, Emma Keenan, Nick A Maskell, Rachael Gooberman-Hill Abstract Purpose: Treatment options for mesothelioma are increasing, as are the number of clinical trials available to patients. However, little is known about patients’ and relatives’ priorities when making decisions about treatment and…

Read More